We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research
Read MoreHide Full Article
Key Takeaways
GEHC plans to form the MAGNUS Neuro Alliance to advance brain research using its head-only 3.0T MR system.
The alliance will unite leading institutions for multi-site trials, joint research and advanced MRI studies.
GEHC aims to develop MRI-based biomarkers to better understand neurological diseases and their progression.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
Per management, the MAGNUS Neuro Alliance aims to foster collaboration among leading neuroscience researchers, creating an environment for developing new research questions, methods and discoveries. The collaboration aims to advance medical research and translate scientific breakthroughs into meaningful health outcomes for patients worldwide.
GEHC Stock Trend Following the News
GEHC stock has lost 2.2% since the announcement on Tuesday. Year to date, the stock has inched down 0.2% compared with the industry’s 15.4% fall. The S&P 500 has risen 9.9% during the same timeframe.
The MAGNUS Neuro Alliance could strengthen GEHC's position in advanced MR imaging by expanding the research applications and clinical potential of its technology. Collaboration with leading academic and medical institutions may increase the visibility of its high-performance MRI systems and create opportunities for broader adoption. Successful research outcomes could also support future clinical applications, reinforcing GEHC's competitive position in the advanced imaging market and creating long-term growth opportunities.
GEHC currently has a market capitalization of $37.35 billion.
Image Source: Zacks Investment Research
More on the News
The MAGNUS Neuro Alliance aims to connect current and future users of the MAGNUS system through multi-site clinical trials, joint research initiatives and the exchange of research protocols, data and expertise. Participating institutions include the University of Iowa, University of Wisconsin-Madison, Stanford University, Brigham and Women's Hospital, King's College London, University of Rochester and West China Hospital of Sichuan University, among others.
Neurological conditions affect more than 3 billion people worldwide, highlighting the need for broader MRI applications. The MAGNUS system combines high-performance gradient technology with a dedicated head-only configuration to overcome certain limitations of conventional whole-body MRI systems in advanced neuroscience research. Its capabilities will support anatomical, diffusion and functional imaging studies, enabling researchers to investigate brain microstructure, microvasculature and function in greater detail.
Research initiatives under the alliance will cover several areas, including neurodegenerative diseases, brain tumors, traumatic brain injury, oncology, multiple sclerosis, sleep research and psychiatric disorders. Researchers will explore subtle changes in brain structure, function and biology that may help identify disease-related biomarkers and improve understanding of disease progression.
The alliance also aims to accelerate the validation of advanced imaging techniques across multiple research sites. By combining expertise across neuroscience disciplines, GEHC seeks to advance the development of MRI-based biomarkers and explore their potential translation into clinical applications.
Industry Prospects Favoring the Market
According to Markets and Markets, the global functional/brain MRI systems market is estimated to reach $850 million in 2026 and is projected to grow at a CAGR of 8% through 2031.
Factors such as the rising prevalence of neurological and psychiatric disorders, growing investments in neuroscience and brain-mapping research, increasing demand for high-resolution brain imaging and wider adoption of functional MRI for presurgical planning and neurological assessments are expected to drive market growth.
Other News
GE HealthCare recently announced the addition of two AI-assisted capabilities, Lung Guidance and AutoAS, to its Vscan Air handheld ultrasound system. The new tools are designed to support lung ultrasound image acquisition and the assessment of moderate-to-severe aortic stenosis (AS) at the point of care.
GE HealthCare recently introduced Allia Celeo, a ceiling-mounted image-guided system designed to support procedural efficiency and precision imaging across cardiology and interventional radiology. Featuring an extra-wide C-arm, AI-powered precision imaging and a real-time digital twin, the system aims to optimize image quality and radiation dose while supporting diverse procedures. It also integrates predictive service technology to minimize operational disruptions.
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Bigstock
GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
Per management, the MAGNUS Neuro Alliance aims to foster collaboration among leading neuroscience researchers, creating an environment for developing new research questions, methods and discoveries. The collaboration aims to advance medical research and translate scientific breakthroughs into meaningful health outcomes for patients worldwide.
GEHC Stock Trend Following the News
GEHC stock has lost 2.2% since the announcement on Tuesday. Year to date, the stock has inched down 0.2% compared with the industry’s 15.4% fall. The S&P 500 has risen 9.9% during the same timeframe.
The MAGNUS Neuro Alliance could strengthen GEHC's position in advanced MR imaging by expanding the research applications and clinical potential of its technology. Collaboration with leading academic and medical institutions may increase the visibility of its high-performance MRI systems and create opportunities for broader adoption. Successful research outcomes could also support future clinical applications, reinforcing GEHC's competitive position in the advanced imaging market and creating long-term growth opportunities.
GEHC currently has a market capitalization of $37.35 billion.
Image Source: Zacks Investment Research
More on the News
The MAGNUS Neuro Alliance aims to connect current and future users of the MAGNUS system through multi-site clinical trials, joint research initiatives and the exchange of research protocols, data and expertise. Participating institutions include the University of Iowa, University of Wisconsin-Madison, Stanford University, Brigham and Women's Hospital, King's College London, University of Rochester and West China Hospital of Sichuan University, among others.
Neurological conditions affect more than 3 billion people worldwide, highlighting the need for broader MRI applications. The MAGNUS system combines high-performance gradient technology with a dedicated head-only configuration to overcome certain limitations of conventional whole-body MRI systems in advanced neuroscience research. Its capabilities will support anatomical, diffusion and functional imaging studies, enabling researchers to investigate brain microstructure, microvasculature and function in greater detail.
Research initiatives under the alliance will cover several areas, including neurodegenerative diseases, brain tumors, traumatic brain injury, oncology, multiple sclerosis, sleep research and psychiatric disorders. Researchers will explore subtle changes in brain structure, function and biology that may help identify disease-related biomarkers and improve understanding of disease progression.
The alliance also aims to accelerate the validation of advanced imaging techniques across multiple research sites. By combining expertise across neuroscience disciplines, GEHC seeks to advance the development of MRI-based biomarkers and explore their potential translation into clinical applications.
Industry Prospects Favoring the Market
According to Markets and Markets, the global functional/brain MRI systems market is estimated to reach $850 million in 2026 and is projected to grow at a CAGR of 8% through 2031.
Factors such as the rising prevalence of neurological and psychiatric disorders, growing investments in neuroscience and brain-mapping research, increasing demand for high-resolution brain imaging and wider adoption of functional MRI for presurgical planning and neurological assessments are expected to drive market growth.
Other News
GE HealthCare recently announced the addition of two AI-assisted capabilities, Lung Guidance and AutoAS, to its Vscan Air handheld ultrasound system. The new tools are designed to support lung ultrasound image acquisition and the assessment of moderate-to-severe aortic stenosis (AS) at the point of care.
GE HealthCare recently introduced Allia Celeo, a ceiling-mounted image-guided system designed to support procedural efficiency and precision imaging across cardiology and interventional radiology. Featuring an extra-wide C-arm, AI-powered precision imaging and a real-time digital twin, the system aims to optimize image quality and radiation dose while supporting diverse procedures. It also integrates predictive service technology to minimize operational disruptions.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.